- Home
- BCAB vs MURA Comparison
BCAB vs MURA Comparison
Compare BCAB & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- MURA
- Stock Information
- Founded
- BCAB 2007
- MURA 2013
- Country
- BCAB United States
- MURA Ireland
- Employees
- BCAB N/A
- MURA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- MURA
- Sector
- BCAB Health Care
- MURA
- Exchange
- BCAB Nasdaq
- MURA Nasdaq
- Market Cap
- BCAB 31.5M
- MURA 35.7M
- IPO Year
- BCAB 2020
- MURA N/A
- Fundamental
- Price
- BCAB $0.72
- MURA $2.07
- Analyst Decision
- BCAB Hold
- MURA Strong Buy
- Analyst Count
- BCAB 3
- MURA 3
- Target Price
- BCAB $1.00
- MURA $12.00
- AVG Volume (30 Days)
- BCAB 1.1M
- MURA 467.9K
- Earning Date
- BCAB 11-06-2025
- MURA 11-12-2025
- Dividend Yield
- BCAB N/A
- MURA N/A
- EPS Growth
- BCAB N/A
- MURA N/A
- EPS
- BCAB N/A
- MURA N/A
- Revenue
- BCAB $11,000,000.00
- MURA N/A
- Revenue This Year
- BCAB N/A
- MURA N/A
- Revenue Next Year
- BCAB N/A
- MURA N/A
- P/E Ratio
- BCAB N/A
- MURA N/A
- Revenue Growth
- BCAB N/A
- MURA N/A
- 52 Week Low
- BCAB $0.24
- MURA $0.95
- 52 Week High
- BCAB $2.53
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- BCAB 56.79
- MURA 51.30
- Support Level
- BCAB N/A
- MURA $2.05
- Resistance Level
- BCAB $0.84
- MURA $2.09
- Average True Range (ATR)
- BCAB 0.07
- MURA 0.01
- MACD
- BCAB -0.00
- MURA 0.01
- Stochastic Oscillator
- BCAB 85.96
- MURA 33.33
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.